ReNeuron Group plc (RNUGF) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerReNeuron Group plc (RNUGF) trades at $0.0011. ReNeuron Group plc is a UK-based biotechnology company focused on developing cell-based therapies for areas of significant unmet medical need. Their pipeline includes treatments for stroke disability and blindness-causing diseases. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for RNUGF: RNUGF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
ReNeuron Group plc (RNUGF) Healthcare & Pipeline Overview
ReNeuron Group plc, a UK-based biotechnology firm, specializes in cell-based therapies, including its CTX stem cell therapy for stroke disability and human retinal progenitor cell therapy for retinitis pigmentosa. Trading on the OTC market, the company focuses on innovative treatments within the regenerative medicine landscape.
What Is the Investment Thesis for RNUGF?
ReNeuron Group plc presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on cell-based therapies for stroke disability and retinitis pigmentosa addresses significant unmet medical needs. Successful completion of Phase 2 trials for the hRPC therapy could be a major catalyst, driving significant value. However, the company's negative ROE of -106.8% and negative free cash flow highlight the financial challenges inherent in biotechnology development. The company's reliance on the OTC market also introduces liquidity and regulatory risks. Investors should carefully weigh the potential for breakthrough therapies against the financial and operational uncertainties.
Based on FMP financials and quantitative analysis
RNUGF Key Highlights
ReNeuron is developing CTX stem cell therapy for stroke disability, a significant unmet medical need.
- The company's human retinal progenitor cell therapy is in Phase 2 clinical trials for retinitis pigmentosa.
- ReNeuron is exploring CTX-derived exosomes for therapeutic applications in pre-clinical studies.
- The company has a collaboration agreement with University College London for anti-cancer cell therapies.
- ReNeuron licenses ReNcell products, providing research tools for cell biology and neuroscience.
Who Are RNUGF's Competitors?
RNUGF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| MESO Mesoblast Limited | $14.08 | -1.68% | $1.83B | 30 5-pillar |
| ICCC ImmuCell Corporation | $9.75 | +1.56% | $88.2M | 79 5-pillar |
| RLYB Rallybio Corporation | $17.08 | +1.91% | $90.6M | 83 5-pillar |
| ALPX Alopexx, Inc. | $9.96 | 0.00% | $119M | 65 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.49 | +0.22% | $184M | 76 5-pillar |
| ANTX AN2 Therapeutics, Inc. | $5.71 | +1.60% | $206M | 67 5-pillar |
| NAGE Niagen Bioscience Inc | $2.79 | +4.10% | $222M | 69 5-pillar |
| QTTB Q32 Bio Inc. | $8.23 | -0.24% | $245M | 67 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RNUGF's Key Strengths?
Proprietary cell-based therapy technologies.
- Focus on unmet medical needs.
- Collaboration with University College London.
- Pipeline of product candidates in various stages of development.
What Are RNUGF's Weaknesses?
Negative ROE and free cash flow.
- Reliance on the OTC market.
- Limited financial resources.
- High risk of clinical trial failure.
What Are the Key Risks for RNUGF?
Financial-distress signal — its Altman Z-Score of -38.75 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-72.4%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure of clinical trials for key product candidates.
- Regulatory delays or rejection of product approvals.
- Competition from established pharmaceutical companies.
- Limited financial resources and need for additional funding.
- Risks associated with trading on the OTC market.
What Threats Does RNUGF Face?
- Regulatory hurdles and delays.
- Competition from established pharmaceutical companies.
- Technological advancements that render current therapies obsolete.
- Economic downturn affecting healthcare spending.
What Are RNUGF's Competitive Advantages?
- Proprietary cell-based therapy technologies.
- Patents protecting key product candidates.
- Clinical trial data demonstrating safety and efficacy.
- Expertise in regenerative medicine and cell therapy.
- Collaboration agreements with leading research institutions.
What Does RNUGF Do?
Founded in 1997 and headquartered in Pencoed, United Kingdom, ReNeuron Group plc is a biotechnology company dedicated to the research, development, and commercialization of cell-based therapies. The company's primary focus is on addressing significant unmet medical needs through innovative regenerative medicine solutions. ReNeuron's lead product candidate is the CTX stem cell therapy, which is being developed for the treatment of stroke disability. This therapy aims to restore neurological function in stroke patients by replacing damaged brain cells with healthy, functional cells. Another key program is the human retinal progenitor cell (hRPC) therapy, currently in Phase 2 clinical trials, targeting retinitis pigmentosa, a genetic eye disease that leads to progressive vision loss and blindness. The company is also exploring the potential of CTX-derived exosomes, nano-sized vesicles secreted by stem cells, in pre-clinical studies. These exosomes hold promise for various therapeutic applications due to their ability to deliver therapeutic molecules to target cells. In addition to its core therapeutic programs, ReNeuron licenses its ReNcell products, providing research tools for cell biology and neuroscience. ReNeuron has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies, expanding its focus into oncology.
What Products and Services Does RNUGF Offer?
- Researches and develops cell-based therapies.
- Focuses on treatments for stroke disability using CTX stem cell therapy.
- Develops human retinal progenitor cell therapy for retinitis pigmentosa.
- Explores CTX-derived exosomes for various therapeutic applications.
- Licenses ReNcell products for research purposes.
- Collaborates with University College London on anti-cancer cell therapies.
How Does RNUGF Make Money?
- Develops and patents cell-based therapies.
- Conducts clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval for commercialization.
- Licenses ReNcell products to generate revenue.
- Forms collaborations and partnerships for research and development.
What Industry Does RNUGF Operate In?
ReNeuron Group plc operates within the rapidly evolving biotechnology industry, specifically in the regenerative medicine and cell therapy space. This sector is characterized by high growth potential, driven by aging populations and increasing demand for innovative treatments for chronic and debilitating diseases. The competitive landscape includes established pharmaceutical companies, as well as smaller biotech firms focused on cell and gene therapies. ReNeuron's focus on stroke disability and retinitis pigmentosa positions it within niche markets with significant unmet needs. The industry is subject to stringent regulatory oversight, with companies required to navigate complex clinical trial processes and regulatory approval pathways.
Who Are RNUGF's Key Customers?
- Patients with stroke disability.
- Patients with retinitis pigmentosa.
- Researchers in cell biology and neuroscience.
- Pharmaceutical companies seeking partnerships.
- Academic institutions involved in research collaborations.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
ReNeuron Group plc operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Pencoed, United Kingdom.
Earnings Track Record
ReNeuron Group plc has beaten Wall Street's EPS estimate in 4 of its last 4 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 28.1% above estimates on average.
Financial Health
ReNeuron Group plc's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -38.75 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for ReNeuron Group plc stands at -72.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -56.1%, showing how much profit it generates from its asset base. A current ratio of 2.05 indicates the company holds enough short-term assets to cover its near-term obligations.
RNUGF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
RNUGF Latest News
No recent news available for RNUGF.
RNUGF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for RNUGF.
Price Targets
Wall Street price target analysis for RNUGF.
RNUGF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for RNUGF; grades run from A+ (80-100) to F (below 30).
RNUGF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that ReNeuron Group plc may not meet the minimum financial or disclosure requirements for higher tiers like OTCQB or OTCQX. Companies in this tier may have limited financial reporting, making it difficult for investors to assess their financial health and performance. Investing in companies on the OTC Other tier carries a higher degree of risk due to the lack of regulatory oversight and potential for fraud or manipulation. This tier is often populated by shell companies, bankrupt entities, or companies with questionable business practices.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or questionable business practices.
- Limited regulatory oversight.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Review the company's legal and regulatory compliance.
- Evaluate the company's stock structure and potential dilution.
- Consult with a qualified financial advisor.
- Understand the risks associated with investing in OTC stocks.
- Established history since 1997.
- Focus on research and development of cell-based therapies.
- Collaboration agreement with University College London.
- Pipeline of product candidates in clinical trials.
- Presence in the biotechnology sector.
RNUGF Healthcare Stock FAQ
What are the main risks for RNUGF?
Investing in ReNeuron Group plc carries several risks inherent to the biotechnology industry and its OTC listing. Clinical trial failures for their key product candidates, such as the CTX stem cell therapy and the human retinal progenitor cell therapy, could significantly impact the company's value.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited or less reliable than exchange-listed stocks.